Search Videos and More
Document
Tip Sheet: Caring for Transgender and Gender Diverse Patients
The Breast Oncology Center developed this reference for providers caring for transgender and gender diverse patients in October 2025.
Document
Expert Review: Early Palliative Care as an Adjunct to Disease-Directed Care in Breast Cancer
The Breast Oncology Center developed this reference for providers based on a presentation by James A. Tulsky, MD, given on February 26, 2025.
Video
Marc Machaalani, MD on MAdCAM-1
Kidney cancer research at ESMO25: Dana-Farber's Marc Machaalani, MD, shares 3 key takeaways from his presentation on the protein MAdCAM-1 and its ability to predict outcomes in patients with metastatic renal cell carcinoma.
Video
KIM-1 in Kidney Cancer Study Presented by Vincent Xu, MD
Dana-Farber Cancer Institute's D. Wenxin (Vincent) Xu shares research suggesting a blood test measuring levels of the KIM-1 biomarker could help assess the burden of disease in advanced kidney cancer and predict outcomes during first-line treatment.
Video
FLAURA2 Lung Cancer Study Presented by Pasi Jänne, MD, PhD
Dana-Farber Cancer Institute's Dr. Pasi Jänne details FLAURA2 which found first-line osimertinib + platinum pemetrexed chemotherapy improved overall survival vs. monotherapy in EGFR mutated non-small cell lung cancer, including poorer prognosis patients.
Video
ASCENT-03 Study Presented by Sara Tolaney, MD, MPH
Dr. Sara Tolaney details research in The New England Journal of Medicine showing the ADC sacituzumab govitecan improved outcomes for patients with advanced triple-negative #BreastCancer ineligible for immune checkpoint inhibitors.
Video
Head and Neck Study Presented by Robert Haddad, MD
Dana-Farber's Dr. Robert Haddad says research shows the combination of a PD1 with anti-LAG3 +/- anti-TIM3 does not improve outcomes in metastatic disease, raising the question of whether to look at this combo earlier, in the neoadjuvant setting.
Video
Paolo Tarantino, MD, PhD, on ADCs
The Next Frontier of Antibody-Drug Conjugate Development - Dana-Farber's Paolo Tarantino, MD, discussed how to optimize the safety of antibody drug conjugates at a session during ESMO25.
News
Dana-Farber Research Uncovers Potential Targeted Therapy for Endometrial Cancer
Jessica St. Laurent, MD, was sure something had gone wrong. The results of an experiment she’d run showed that the cancer cells she was studying had abnormally high levels of a specific collection of proteins of interest to her team.
News
Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer
The Dana-Farber-co-led phase 3 IMvigor011 trial results show that periodic ctDNA screening after surgery can help guide a decision to begin adjuvant immunotherapy.
News
ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors
Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to standard chemotherapy.
News
Novel Treatment Combination Improves Progression-Free Survival in Metastatic, Estrogen-Receptor-Positive HER-2-Negative Breast Cancer
Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach.